These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26157326)

  • 1. Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patients.
    Li L; Zhang Z; Bie Z; Wang Z; Zhang P; Nie X; Li Y; Wang H; Ai B; Cheng G
    Chin J Cancer Res; 2015 Jun; 27(3):294-300. PubMed ID: 26157326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A standard protocol for detection of EGFR mutations in cytologic specimens].
    Wang Z; Wu X; Shi Y; Han X; Cheng G; Li L; Zhang L; Zhang Y; Mu X; Zhu G; Fan Z; Yang L; Di J; Jia X; Liu D
    Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):516-21. PubMed ID: 25327657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical Value of Droplet Digital PCR and Super-ARMS Detection of Epidermal Growth Factor Receptor Gene Mutation in Plasma Circulating Tumor DNA of Patients with Advanced Lung Adenocarcinoma].
    Cao Z; Wang J; Qin N; Li K; Lv J; Wang J; Yang X; Li X; Zhang H; Zhang Q; Long H; Shu C; Ma L; Zhang S
    Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):84-90. PubMed ID: 32093452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients.
    Wu W; Cao Z; Zhang W; Zhang L; Hou L; Wu C
    Diagn Pathol; 2020 Jan; 15(1):9. PubMed ID: 32005253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC).
    Chen L; Chen R; Zhu Z; Zhang Y; Wen Z; Li Y; Li X; Luo Y; Ma L; Lin S; Chen X
    Chin J Cancer Res; 2014 Aug; 26(4):466-70. PubMed ID: 25232221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Chu H; Zhong C; Xue G; Liang X; Wang J; Liu Y; Zhao S; Zhou Q; Bi J
    Oncol Rep; 2013 Nov; 30(5):2311-5. PubMed ID: 24002698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of
    Xu H; Baidoo AAH; Su S; Ye J; Chen C; Xie Y; Bertolaccini L; Ismail M; Ricciuti B; Ng CSH; Flores RM; Li Y;
    Transl Lung Cancer Res; 2019 Apr; 8(2):135-143. PubMed ID: 31106124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
    Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
    Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
    [No Abstract]   [Full Text] [Related]  

  • 10. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens.
    Xu H; Sun W; Zhang G; Cheng Y
    J BUON; 2015; 20(1):142-5. PubMed ID: 25778309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploratory cohort study and meta-analysis of
    Sun S; Yu H; Wang H; Zhao X; Zhao X; Wu X; Qiao J; Chang J; Wang J
    Onco Targets Ther; 2017; 10():1955-1967. PubMed ID: 28435285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing.
    Liang C; Wu Z; Gan X; Liu Y; You Y; Liu C; Zhou C; Liang Y; Mo H; Chen AM; Zhang J
    Yonsei Med J; 2018 Jan; 59(1):13-19. PubMed ID: 29214771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
    Kim DW; Lee SH; Lee JS; Lee MA; Kang JH; Kim SY; Shin SW; Kim HK; Heo DS
    Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
    Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
    Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.
    Sun H; Sun X; Zhai X; Guo J; Liu Y; Ying J; Wang Z
    Thorac Cancer; 2016 Jan; 7(1):61-5. PubMed ID: 26816540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
    Yoshimura N; Kudoh S; Mitsuoka S; Yoshimoto N; Oka T; Nakai T; Suzumira T; Matusura K; Tochino Y; Asai K; Kimura T; Kawaguchi T; Hirata K
    Lung Cancer; 2015 Oct; 90(1):65-70. PubMed ID: 26238424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
    He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
    Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.